Carla Araujo

Bayonne, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.

Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.

Journal: The Lancet. Oncology

Published: April 01, 2025

Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.

Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.

Journal: Haematologica

Published: June 14, 2024

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 18, 2023

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.

Journal: British journal of haematology

Published: November 20, 2022

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.

Journal: Haematologica

Published: December 22, 2021

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Journal: Blood

Published: November 01, 2021

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Journal: Leukemia

Published: May 18, 2021

Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.

Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.

Journal: British journal of haematology

Published: July 09, 2019

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2018

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Journal: Blood

Published: July 14, 2018

Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.

Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.

Journal: Annals of hematology

Published: June 17, 2018

Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Journal: British journal of haematology

Published: February 13, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026